Health

New Vaccine From Pfizer Protects Newborn From Severe Illness?

On Tuesday, November 1, Pfizer stated that their RSV vaccine for pregnant women provides at least 6 months of protection against severe illnesses in babies.

The vaccine prevented severe RSV cases in newborns whose mothers were vaccinated by 82% in phase III of a randomized, double-blind, and placebo-controlled research.

For your information, RSV is a common virus that affects the lungs. It makes people like they have a mild cold. Even though most kids and adults who are infected with RSV get better without any major long-term effects, Chang said that the virus could be serious and even kill babies, young kids, and older adults.

This protection lasts from birth until 3 months. Pfizer added that the vaccination was 69% effective at 6 months of age, despite a decrease in protection.

According to Yahoo News, participants in the trial were monitored for six months following vaccination to determine the vaccine’s safety and effectiveness. Moreover, the infants were monitored for at least a year, and more than half were monitored for two years.

“As someone who spent part of their ID training focused on RSV research, this is wonderful news,”

— Dr. Michael Chang, pediatric infectious diseases specialist

Dr. Chang also said that the vaccination might be a “game changer”, but they must consider other things as well. This includes children older than 1 year who have a high disease burden.

RSV mortality is highest among premature infants and newborns who have cyanotic congenital heart disease.  This immunization may not assist these patients, he added.

Chang emphasized that maternal immunization for pertussis (whooping cough) has been utilized successfully in the past. In addition, new results indicate that mothers who get COVIDvaccinations during pregnancy can likewise convey protective antibodies to their infants.

Pfizer’s plan

Pfizer plans to test the vaccine in pregnant women, younger individuals, and elderly people who are at risk for serious infection. In August, the company revealed positive vaccination trial results in older adults.

Pfizer has stated that it intends to submit a licensing application to the FDA before the year’s end. Vaccine distribution is anticipated for late 2023 or early 2024 if it receives regulatory approval.

Source: Yahoo News, NBC News

Adib Mohd

Recent Posts

Meet Lee Jun Young Up Close in Kuala Lumpur, Tickets Now Available

Malaysian fans, the wait is finally over! Lee Jun Young, the multitalented actor, singer and… Read More

1 day ago

Lee Jung-jae and Lim Ji-yeon Reignite the Rom-Com Spark in Nice to Not Meet You, Exclusively on Prime Video

Prime Video has unveiled Nice to Not Meet You, an upcoming Korean rom-com series starring… Read More

1 day ago

Goodbye One-Off EPF, Hello Monthly Pension? Here’s What’s Brewing

If you’ve ever worried about spending all your EPF savings too fast after retirement, the… Read More

1 day ago

Generali Malaysia Strengthens East Malaysia Presence with New-Look Sandakan Branch

Generali Insurance Malaysia Berhad today announced the launch of its newly renovated branch in the… Read More

2 days ago

More Than a Makeover, L’Oréal Launches First-of-Its-Kind Social Salon in Asia

Malaysia is now home to Asia’s first-ever Beauty for a Better Life Salon, a dedicated… Read More

2 days ago

The Ordinary Opens Its First-Ever Pop-Up in Malaysia

The Ordinary has officially landed in Malaysia, not just in stores, but with its first-ever… Read More

2 days ago

This website uses cookies.